/cdn.vox-cdn.com/uploads/chorus_asset/file/25769021/Screenshot_2024_12_02_at_9.10.08_AM.jpeg "Tesla is launching an Apple Watch app")
Dublin, Dec. 02, 2024 (GLOBE NEWSWIRE) — The “Ovarian Cancer Therapeutics – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering.
The global market for Ovarian Cancer Therapeutics is estimated at US$6.6 Billion in 2023 and is projected to reach US$20.5 Billion by 2030, growing at a CAGR of 15.3% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
The oncology inhibitors market is witnessing substantial growth, with the PARP Inhibitors segment projected to reach US$12.8 Billion by 2030, driven by a robust CAGR of 16.5%. The Angiogenesis Inhibitors segment is also poised for significant expansion, expected to grow at a 13.7% CAGR over the next eight years.
From a regional perspective, the U.S. market is estimated at $1.7 Billion in 2023, showcasing steady growth. Meanwhile, China is forecasted to grow at an impressive 20.1% CAGR, reaching $5.5 Billion by 2030. Additional growth trends are observed in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Key Insights on the Oncology Inhibitors Market
- Comprehensive Market Data: Provides independent analysis of annual sales and market forecasts, expressed in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into market performance across key regions, including North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
- Company Profiles: Includes coverage of leading market players such as Amgen, Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, and others.
- Complimentary Updates: Readers benefit from one year of free updates to stay informed about the latest developments in the market.
Key Questions Answered:
- How is the Global Ovarian Cancer Therapeutics Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 118 |
| Forecast Period | 2023 – 2030 |
| Estimated Market Value (USD) in 2023 | $6.6 Billion |
| Forecasted Market Value (USD) by 2030 | $20.5 Billion |
| Compound Annual Growth Rate | 15.3% |
| Regions Covered | Global |
Key Topics Covered:
MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Ovarian Cancer Therapeutics – Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence – Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
- Global Economic Update
FOCUS ON SELECT PLAYERS (Total 12 Featured)
- Amgen, Inc.
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Chugai Pharmaceutical Co., Ltd.
- Clovis Oncology
- Dr. Reddy’s Laboratories Ltd.
- Eli Lilly and Company
- Genentech, Inc.
- GlaxoSmithKline PLC
- MedImmune
- Roche Diagnostics Corporation
- Tesaro, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/k33rye
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Ovarian Cancer Therapeutics Market
